Skip to main content
. 2020 Dec 31;21(2):159. doi: 10.3892/ol.2020.12420

Figure 4.

Figure 4.

Association between B3GNT3 expression and clinicopathologic characteristics. (A) Clinical stage: Stage 1 (35.09±26.66) vs. Stage 2/3/4 (49.24±28.86). (B) Tumor/topography: T1/T2 (37.82±26.32) vs. T3/T4 (49.64±29.09). (C) Grade: G1 (34.60±26.75) vs. G2/3/4 (49.65±28.91). (D) MSI: MSI-L (69.43±21.43) vs. MSS (47.69±28.83). B3GNT3 expression was associated with malignant behavior of pancreatic cancer. *P<0.05. B3GNT3, βGal β-1,3-N-acetylglucosaminyltransferase 3; MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, low-frequency MSI.